Cancer and bones: Chemotherapy, smoking may increase fracture risk

While many people survive cancer, older people often experience bone fracture injuries later. A new study finds that, especially in the first five years after an advanced cancer diagnosis, there is an increased chance of bone fractures for older patients. The most likely injuries are vertebral fractures and hip fractures. There are an estimated 18.1 million cancer survivors currently in […]

Continue reading »

Intravenous iron improves long-term outcomes for people with heart failure and iron deficiency

Long-term treatment with iron administered intravenously improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov. 5–7, 2022, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical […]

Continue reading »

Valerie Bertinelli Just Shared the Most Delicious Way to Use Up Leftover Thanksgiving Stuffing

Valerie Bertinelli is the queen of saving your Thanksgiving leftovers and transforming them into something totally delicious! She has shared a smart way to save those extra mashed potatoes, a mouth-watering turkey calzone trick, and now she has a fantastic idea for leftover stuffing. We are thoroughly impressed! Stuffing is delicious on its own, but the classic dish — usually […]

Continue reading »

Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer progression-free survival (PFS) after treatment with BCMA-targeted T-cell therapy, according to results published in Blood Cancer Discovery. The findings were concurrently presented at the International Myeloma Society […]

Continue reading »

An optimal approach to treat femoropopliteal lesions

New research published in the Journal of the American College of Cardiology shows the use of drug-coated balloons is an optimal approach compared to bare metal stents in treating femoropopliteal lesions. In the paper entitled "Drug-coated Balloons versus Bare Metal Stents in Femoropopliteal Lesions: Three-Year Results of Prospective, Multicenter Studies" researchers reported outcomes testing drug-coated balloons (DCB) versus bare metal […]

Continue reading »

Transcriptomic dysregulation across cerebral cortex in autism spectrum disorder

A recent study in Nature demonstrated transcriptomic dysregulation in the cerebral cortex in autism spectrum disorder (ASD). Study: Broad transcriptomic dysregulation occurs across the cerebral cortex in ASD. Image Credit: Ukrolenochka/Shutterstock Background The risk factors for ASD include a significant genetic component with hundreds of risk genes involved. Molecular profiling studies have observed consistent epigenetic and transcriptomic dysregulation patterns along […]

Continue reading »

How Private Equity Is Investing in Health Care: A Video Primer

https://youtube.com/watch?v=TPVzH88TL4A%3Fversion%3D3%26%23038%3Brel%3D1%26%23038%3Bshowsearch%3D0%26%23038%3Bshowinfo%3D1%26%23038%3Biv_load_policy%3D1%26%23038%3Bfs%3D1%26%23038%3Bhl%3Den-US%26%23038%3Bautohide%3D2%26%23038%3Bwmode%3Dtransparent In the past decade, private equity has moved aggressively into health care, gobbling up physician practices and even entire hospitals. But what exactly is private equity? And what does its involvement mean for patients and for the American health care system? KHN explains. Source: Read Full Article

Continue reading »

Olaparib Plus RT Well Tolerated in Triple-Negative Breast Cancer

Results from an early-phase trial conducted in patients with triple-negative breast cancer (TNBC) show that the combination of olaparib and radiotherapy was well tolerated. Olaparib, a PARP Inhibitor, has already shown efficacy in some types of breast cancer, but in this study, the drug was investigated as a radiosensitizer to increase the efficacy of radiotherapy. At a median follow-up of […]

Continue reading »
1 298 299 300 301 302 1,322